ARQT Form 144: 435 Shares Listed for Resale

Arcutis Biotherapeutics submitted a Form 144 notice relating to proposed sales of Common Stock.

Rhea-AI Filing Summary

Arcutis Biotherapeutics submitted a Form 144 notice relating to proposed sales of Common Stock. The filing lists 435 shares tied to Restricted Stock Vesting with an effective date of 05/01/2026. The filing also shows prior dispositions of 2,853 shares on 03/02/2026 and 1,341 shares on 05/04/2026.

Insights

Securities Compliance Counsel

Form 144 lists proposed resale of vested restricted shares and recent dispositions.

The notice documents 435 shares associated with restricted stock vesting on 05/01/2026, and two prior dispositions of 2,853 and 1,341 shares in 03/02/2026 and 05/04/2026. This aligns with typical Rule 144 resale notifications for insiders or affiliates.

Regulatory next steps depend on market sales and compliance with Rule 144 holding/volume requirements; the filing itself is a statutory notice and does not by itself effect sales.

Key Figures

Proposed resale: 435 shares Disposition (past 3 months): 2,853 shares Disposition (past 3 months): 1,341 shares +2 more

5 metrics

Proposed resale 435 shares Restricted Stock Vesting on <date>05/01/2026</date>

Disposition (past 3 months) 2,853 shares Disposed on <date>03/02/2026</date>

Disposition (past 3 months) 1,341 shares Disposed on <date>05/04/2026</date>

Numeric entry 9,156.75 Listed near securities information in the excerpt

Identifier 125083374 Numeric string shown in securities section

Key Terms

Form 144, Rule 144, Restricted Stock Vesting

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"Securities To Be Sold | Restricted Stock Vesting"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 05/01/2026 | Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

FAQ

What does ARQT's Form 144 say about shares being offered for sale?

The Form 144 lists 435 shares connected to restricted stock vesting with an effective date of 05/01/2026. It identifies these shares as Common Stock proposed for resale under Rule 144.

Does the filing show any recent sales by the reporting person for ARQT?

Yes. The filing records prior dispositions of 2,853 shares on 03/02/2026 and 1,341 shares on 05/04/2026. These entries appear in the 'Securities Sold During The Past 3 Months' section.

Who is the reporting person named in the ARQT Form 144?

The filing identifies a reporting address linked to Latha Vairavan at the provided Westlake Village address. The Form 144 lists this person in connection with Common Stock dispositions.

Does the Form 144 state how sales will be executed or proceeds used for ARQT?

The excerpt lists share counts and dates but does not specify execution methods or use of proceeds. The filing functions as a statutory resale notice under Rule 144 rather than an offer document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002065881
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ARCUTIS BIOTHERAPEUTICS, INC.
SEC File Number	001-39186
Address of Issuer	3027 Townsgate Road Suite 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Latha Vairavan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	435	9156.75	125083374	05/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			435	05/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Latha Vairavan 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	03/02/2026	2853	71845
Latha Vairavan 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	05/04/2026	1341	31662

144: Remarks and Signature

Remarks
Date of Notice	05/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Latha Vairavan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)